Segra International is pleased to announce its first successful shipment of numerous premium Cannabis tissue culture plantlets to Portugal for greenhouse cultivation trials with a leading multi-national cannabis operator. Under this agreement, Segra has collaborated with the cultivation partner to tailor a suite of cultivars specific to their growing environment in Portugal, with a heightened focus on chemical expression, pathogen resistance, and optimized morphology for scaled cultivation. A second shipment is booked for August 2021 to replicate this trial and further validate these cultivars for additional, recurring supply in the future. This shipment represents the third country Segra has successfully exported plantlets to in 2021 along with South Africa and Germany.
"Tissue culture plantlets are an increasingly attractive option for cultivators in the EU as they offer the cleanest and most consistent possible input when manufacturing pharmaceutical-grade cannabis products under EU-GMP certifications," said Jamie Blundell, CEO of Segra International. "As emerging markets seek legal options to onboard proven genetics, Segra is providing a solution with our Verified Segra Stock™ Guarantee where there is virtually no risk of pathogen introduction to both a cultivator's facility and the emerging cannabis industry as a whole. With Segra's extensive genetic portfolio, we can offer these in-demand cultivars to emerging markets worldwide, resulting in clean, uniform crops that create reproducible products for recreational and medical cannabis markets alike.”
Learn more about Segra’s services and premium cultivars by viewing the 2021 Cultivar and Services Catalogue.
For more information:
Segra International Corp.
#108 – 21300 Gordon Way
Richmond, BC, Canada